Cart
sales@molnova.com
Crocin IV
CAS No. 57710-64-2
Crocin IV( ——— )
Catalog No. M38634 CAS No. 57710-64-2
Crocin IV (Standard) is the analytical standard of Crocin IV. This product is intended for research and analytical applications. Crocin IV (Dicrocin), a crocetin glycoside, is a carotenoid pigment. Crocin IV has potent antioxidant activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 730 | In Stock |
|
| 25MG | Get Quote | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCrocin IV
-
NoteResearch use only, not for human use.
-
Brief DescriptionCrocin IV (Standard) is the analytical standard of Crocin IV. This product is intended for research and analytical applications. Crocin IV (Dicrocin), a crocetin glycoside, is a carotenoid pigment. Crocin IV has potent antioxidant activity.
-
DescriptionCrocin IV (Dicrocin), a crocetin glycoside, is a carotenoid pigment. Crocin IV has potent antioxidant activity.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number57710-64-2
-
Formula Weight652.68
-
Molecular FormulaC32H44O14
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
UCL 2077
UCL 2077 is a subtype-selective blocker of the epilepsy-associated KCNQ channels and it also is a selective slow-afterhyperpolarization channel blocker.
-
6,7-Dihydroxybergamo...
6',7'-Dihydroxybergamottin(DHB), a well-known inhibitor of CYP3A4, the inhibition of CYP3A4 activity by DHB includes the inhibition of POR activity, DHB can inhibit nifedipine oxidation in a concentration-dependent manner.
-
Rilematovir
JNJ-678 is a novel inhibitor of the fusion protein. JNJ-678 shows the potential for respiratory syncytial virus (RSV) treatment.
